Develops novel bacteriophage therapeutics to treat antibiotic-resistant bacterial infections.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology firm specializing in the advancement of targeted bacteriophage therapeutics designed to combat antibiotic-resistant infections on a global scale. Leveraging its proprietary bacteriophage-based technology, the company is at the forefront of developing innovative treatments aimed at addressing critical medical challenges.
Key product candidates in Armata Pharmaceuticals' pipeline include AP-SA02 for treating Staphylococcus aureus bacteremia, AP-PA02 targeting Pseudomonas aeruginosa infections, and AP-PA03 designed for pneumonia treatment. These initiatives underscore the company's commitment to pioneering effective therapies against resilient bacterial strains that pose significant public health risks.
In pursuit of its mission, Armata Pharmaceuticals has established strategic partnerships, including a notable collaboration with Merck & Co. to develop synthetic bacteriophage candidates aimed at combating undisclosed infectious disease agents. Headquartered in Marina del Rey, California, the company continues to drive forward its research and development efforts to deliver impactful solutions in the fight against antibiotic resistance.